Menlo Park, California, United States Decheng Capital is the famous VC, which was founded in 2011. The venture was found in Asia in China. The main office of represented VC is situated in the Shanghai.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Decheng Capital, startups are often financed by Sofinnova Investments, Lilly Asia Ventures, Kleiner Perkins. The meaningful sponsors for the fund in investment in the same round are Vivo Capital, OrbiMed, Celgene. In the next rounds fund is usually obtained by XSeed Capital, Wooshin Venture Investment Corp., South China Venture Capital.
Among the most popular portfolio startups of the fund, we may highlight luckin coffee, ARMO BioSciences, Mindstrong Health. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Medical Device, Biopharma. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. The fund has exact preference in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low.
Comparing to the other companies, this Decheng Capital performs on 10 percentage points less the average number of lead investments. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2018. The real fund results show that this VC is 28 percentage points more often commits exit comparing to other companies. The typical startup value when the investment from Decheng Capital is more than 1 billion dollars. The top amount of exits for fund were in 2019. The fund is generally included in 2-6 deals every year.
The overall number of key employees were 3.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Bottomline Technologies | New Hampshire, Portsmouth, United States |
| Bridgewest Group | California, San Diego, United States |
| Christian Nielsen Fund | - |
| DTE Energy Ventures | Ann Arbor, Michigan, United States |
| Elan Growth Partners | California, Carlsbad, United States |
| Geekdom | Australia, New South Wales, Sydney |
| Hike | Delhi, India, New Delhi |
| Inga Britt & Arne Lundberg Research Foundation | Mölndal, Sweden, Vastra Gotaland |
| Knowles Electronics | Illinois, Itasca, United States |
| Lighthouse Capital Group | California, Long Beach, United States |
| Louis Vuitton | France, Ile-de-France, Paris |
| Ministry of Digital and Digitalization | Benin, Cotonou, Littoral |
| Musha Ventures | New York, New York, United States |
| Pacific Advantage Capital | Connecticut, Stamford, United States |
| PME MTL | Canada, Montréal, Quebec |
| Saban Ventures | California, Los Angeles, United States |
| Sandalphon Capital | Chicago, Illinois, United States |
| Snow Leopard Technology Ventures | India, Maharashtra, Pune |
| Western Digital Capital | California, Irvine, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Medtech Technology | $30M | 14 Sep 2024 | China, China | ||
Phrontline Biopharma | $15M | 27 Jun 2024 | Shanghai, Shanghai, China | ||
Firefly Bio | $94M | 15 Feb 2024 | San Francisco, California, United States | ||
Yaotang Biology | $15M | 30 Nov 2023 | Minhang, Shanghai, China | ||
Adela | $48M | 25 Sep 2023 | Toronto, Ontario, Canada | ||
GRIT Biotechnology | $61M | 08 Sep 2023 | Shanghai, Shanghai, China | ||
Cellares | $255M | 23 Aug 2023 | South San Francisco, California, United States | ||
Upstream Bio | $200M | 08 Jun 2023 | Waltham, Massachusetts, United States | ||
LevitasBio | $35M | 24 Oct 2022 | San Francisco, California, United States |
– Adela specializes in detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test.
– The company raised $60M in Series A funding.
– The round was led by F-Prime Capital with participation from OrbiMed, Deerfield Management, Decheng Capital and RA Capital Management.
– The company plans to use the advance its technology towards commercialization, with initial applications across the cancer care continuum from early detection to disease monitoring.
– Cue Health Inc. from San Diego closed a $235m financing round.
– The round was led by Perceptive Advisors, MSD Capital, and Koch Strategic Platforms, a subsidiary of Koch Industries, existing investors Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Decheng Capital, Cavu Ventures, ACME Capital, and others.
– The new investment will be used to accelerate growth of the company.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Medtech Technology | $30M | 14 Sep 2024 | China, China | ||
Phrontline Biopharma | $15M | 27 Jun 2024 | Shanghai, Shanghai, China | ||
Firefly Bio | $94M | 15 Feb 2024 | San Francisco, California, United States | ||
Yaotang Biology | $15M | 30 Nov 2023 | Minhang, Shanghai, China | ||
Adela | $48M | 25 Sep 2023 | Toronto, Ontario, Canada | ||
GRIT Biotechnology | $61M | 08 Sep 2023 | Shanghai, Shanghai, China | ||
Cellares | $255M | 23 Aug 2023 | South San Francisco, California, United States | ||
Upstream Bio | $200M | 08 Jun 2023 | Waltham, Massachusetts, United States | ||
LevitasBio | $35M | 24 Oct 2022 | San Francisco, California, United States |
